Company news
Palisade Bio, Inc. (NASDAQ:PALI) news
Every Palisade Bio, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Palisade Bio to Participate in Upcoming Investor Conferences
September 3, 2026
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
August 10, 2026
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
July 10, 2026
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
June 29, 2026
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
June 11, 2026
Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
June 9, 2026
Palisade Bio to Participate in the Jefferies Global Healthcare Conference
May 27, 2026
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
May 12, 2026
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily D...
May 5, 2026
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
April 16, 2026
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
April 8, 2026
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease
March 30, 2026
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
March 2, 2026
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI...
February 23, 2026
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
February 17, 2026
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
February 9, 2026
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 5, 2026
Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board
January 29, 2026
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences
January 16, 2026
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108
January 7, 2026
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108
December 30, 2025
Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
December 2, 2025
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
Palisades Expands Nevada Gold Portfolio Through Acquisition of Undercover Gold by Made in America Gold Corp.
November 17, 2025
PALISADES ANNOUNCES EXTENSION OF CONVERTIBLE NOTE
November 11, 2025
Palisades Appoints Justin Daley as CEO of 100%-OwnedMade in America Gold
November 3, 2025
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
October 28, 2025
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment...
October 20, 2025
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
October 13, 2025
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
October 13, 2025
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
October 9, 2025
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
October 2, 2025
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock
October 1, 2025
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
September 26, 2025
Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data
September 17, 2025
PALISADES PROVIDES UPDATE ON RETURN OF CAPITAL TRANSACTION AND TRADING HALT
September 15, 2025
PALISADES ANNOUNCES THE SHARE DISTRIBUTION RATIO FOR RETURN OF CAPITAL TRANSACTION
September 10, 2025
PALISADES PROVIDES UPDATE ON RETURN OF CAPITAL TRANSACTION AND LISTED WARRANTS
September 9, 2025
Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)
September 5, 2025
PALISADES ANNOUNCES RESULTS OF SHAREHOLDER MEETING AS WELL AS BOARD AND MANAGEMENT CHANGES
August 28, 2025
Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
August 25, 2025
Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108
August 7, 2025
Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
July 31, 2025
PALISADES ANNOUNCES CLOSING OF $8,251,800 LOAN WITH STRATEGIC INVESTOR
July 30, 2025
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
July 23, 2025
Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
July 22, 2025
Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors
July 9, 2025
Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for F...
May 27, 2025
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the ...
May 6, 2025
Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inf...
May 1, 2025